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Abstract
Background: Detection of critical cancer gene mutations in clinical tumor specimens may predict patient outcomes and
inform treatment options; however, high-throughput mutation profiling remains underdeveloped as a diagnostic approach.
We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in
the clinical setting.
Methodology: We developed and implemented an optimized mutation profiling platform (‘‘OncoMap’’) to interrogate
,400 mutations in 33 known oncogenes and tumor suppressors, many of which are known to predict response or
resistance to targeted therapies. The performance of OncoMap was analyzed using DNA derived from both frozen and FFPE
clinical material in a diverse set of cancer types. A subsequent in-depth analysis was conducted on histologically and
clinically annotated pediatric gliomas. The sensitivity and specificity of OncoMap were 93.8% and 100% in fresh frozen
tissue; and 89.3% and 99.4% in FFPE-derived DNA. We detected known mutations at the expected frequencies in common
cancers, as well as novel mutations in adult and pediatric cancers that are likely to predict heightened response or resistance
to existing or developmental cancer therapies. OncoMap profiles also support a new molecular stratification of pediatric
low-grade gliomas based on BRAF mutations that may have immediate clinical impact.
Conclusions: Our results demonstrate the clinical feasibility of high-throughput mutation profiling to query a large panel of
‘‘actionable’’ cancer gene mutations. In the future, this type of approach may be incorporated into both cancer
epidemiologic studies and clinical decision making to specify the use of many targeted anticancer agents.
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Introduction
Many tumors contain hallmark mutations within oncogenes or
tumor suppressor (TS) genes that may confer a heightened
susceptibility to targeted anticancer therapies. Well-established
examples include KIT mutations in gastrointestinal stromal tumors
(GISTs) that predict response to imatinib or nilotinib, and non-small
cell lung cancers with EGFR mutations that are sensitive to
erlotinib[1,2,3]. The presence of other mutations predicts a lack of
response to targeted therapy. For example, lung and colorectal
cancers that harbor mutations in the KRAS oncogene are unres-
ponsive to treatment with anti-EGFR agents[4], and inactivating
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PTEN mutations (or protein loss) in glioblastomas predict resistance
to erlotinib[5]. Thus, clinical decision-making based on tumor
genetic information will increasingly be informed by the mutational
status of multiple cancer genes. However, generating a comprehen-
sive profile of target-able or otherwise ‘‘actionable’’ tumor DNA
mutations in the clinical arena remains challenging.
Recent technological advances make it feasible in principle to
screen a tumor biopsy for many types of genomic changes.
However, incorporation of such information into clinical decision-
making requires reliable genomic profiling of frozen, paraffin-
derived, and archival tumor DNA. In this context, nucleic acids
are often subject to degradation and/or chemical modification,
and the availability of tumor tissue may be limiting.
We previously reported the adaptation of a high-throughput
genotyping approach to interrogate key mutations in a panel of 17
known oncogenes. We now demonstrate the clinical feasibility of
mass-spectrometric based cancer gene mutation profiling for a
large panel of oncogene and TS gene mutations. To accomplish
this, we generated an approach termed OncoMap, which employs
an expanded collection of 460 assays interrogating known
mutations in 33 cancer genes. Using this genomic profiling
approach coupled to an analytical mutation-calling algorithm and
orthogonal validation step, we identified numerous mutations
present in genomic DNA from both frozen and FFPE tumor tissue.
Moreover, the application of systematic mutation profiling to
.120 pediatric low-grade astrocytomas reveals a clinically infor-
mative molecular stratification not previously recognized in this
tumor type. Such information, if it became widely available, could
inform both clinical decision making and optimal clinical trial
design for targeted therapeutics.
Methods
Patients and Tumor Tissue Collection
Anonymized tumor specimens were obtained from the Cooper-
ative Human Tissue Network (CHTN), Surgical Oncology
University of Siena, Italy, and Dana-Farber Cancer Institute;
human glioma samples were obtained from the clinical archives of
the departments of Pathology at Children’s Hospital Boston and
Brigham and Women’s Hospital. (The required tumor content was
.70%; necrosis ,10%.) Institutional review board (IRB) exemp-
tion was obtained for all samples from the Dana-Farber/Partners
Cancer Care Office for the Protection of Research Subjects. DNA
extraction was performed as described in Methods S1.
OncoMap Assay Design and Genotyping
Selection of cancer gene mutations for assay design and mass
spectrometric genotyping were performed as previously described[6]
with modifications indicated in Methods S1. Assay, primer and
probe sequences are indicated in Table S1.
Sample Barcoding and Sequencing
Primers flanking KRAS codon 12 were used to PCR-amplify
genomic DNA from 91 fresh frozen and 93 FFPE samples (primer
sequences indicated in Table S2). PCR amplicons were analyzed
by Sanger sequencing. Alternatively, KRAS codon 12 was PCR-
amplified with barcoded primers as described in Methods S1. PCR
amplicons were pooled and analyzed (Illumina Genome Analyzer II;
single lane). Sequence data was analyzed as described in Methods S1.
Results
Characteristics of Clinical Tumor Samples
A total of 903 clinical tumor specimens derived from 12
different tissue sites were assessed for this study (Table 1). The
majority of samples were adenocarcinomas (n = 625) from tumors
of the breast, lung, prostate, and GI tract. A collection of GISTs
(n= 34) and gliomas (n = 155) were also included. Of these, 643
specimens were obtained from fresh frozen tissue and 260 derived
from FFPE blocks. Estimated tumor content exceeded 70% in all
samples as measured by pathological review (see Methods).
Performance of the Tumor Mutation Profiling Algorithm
To facilitate cancer gene mutation profiling in clinical tumor
specimens, we developed OncoMap, a panel of genotyping assays
that assessed 396 unique mutations in 33 cancer genes. The
complete mutation profiling algorithm (Figure 1A) involved mass
spectrometric genotyping followed by both automated calling and
manual review to generate a list of candidate mutations. These
candidates were subjected to secondary genotyping validation (see
Methods S1). Assuming that all primary profiling and assay
validation reagents are in place, 7–10 days are required to complete
the entire OncoMap sequence.
Table 1. Human tumor samples (fresh frozen and FFPE) investigated in this study.
Total Number of
Samples Tested
Number of fresh frozen
vs (FFPE) samples
Total Number of
Samples with Mutation
Percentage of
samples with mutation
Brain 155 0 (155) 44 28.40%
Breast 53 20 (33) 21 39.60%
Colon 159 113 (46) 102 64.20%
Endometrium 23 23 (0) 18 78.30%
Esophagus 117 117 (0) 29 24.80%
Gastric 233 233 (0) 90 38.20%
Kidney 26 26 (0) 1 3.80%
Lung 26 0 (26) 15 57.70%
Ovary 9 9 (0) 1 11.10%
Prostate 95 95 (0) 10 10.50%
Thyroid 7 7 (0) 4 57.10%
Total Numbers: 903 643 (260) 335 37.10%
doi:10.1371/journal.pone.0007887.t001
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OncoMap performance was assessed after determining the
‘‘ground-truth’’ mutational status at KRAS codon 12 using a DNA
barcoding and massively parallel sequencing-by-synthesis strategy
(see Methods S1) applied to 91 frozen and 93 FFPE-derived tumor
DNAs. When these deep sequencing results were compared to
genotyping assays interrogating the same KRAS codon, we found the
OncoMap sensitivity and specificity to be 93.8% and 100%,
respectively, in DNA from fresh/frozen tissue; and 89.3% and
99.4% in FFPE-derived DNA (Figure 1B). In contrast, the
sensitivity of conventional Sanger sequencing was 83.3% for fresh
frozen tissue and 76.0% for FFPE-derived DNA, confirming the
heightened performance of genotyping-based mutation profiling [7].
OncoMap performance was evaluated more extensively by
testing 215 fresh frozen tumor samples spanning multiple tumor
types in which the mutational status for nucleotides interrogated
by 52 OncoMap assays had been established previously. By this
analysis, mutation profiling achieved a similarly high specificity of
99.8%. Assay sensitivity was optimal in tumor tissues where the
tumor content exceeded 50% (data not shown). Although
individual sensitivity values could not be determined for all
mutations assayed, calculations using unidirectional KRAS assays
(reflective of the majority of OncoMap assays) yielded nearly
identical sensitivity and specificity values (Figure S1). These
results suggested that the genotyping-based mutation profiling
platform was suitable for many clinical applications.
‘‘Actionable’’ Cancer Gene Mutations across Diverse
Cancer Types
Of the 903 clinical tumor specimens profiled, 37% (n= 335)
contained one or more mutations. In total, 417 mutations were
identified, with 63 samples exhibiting co-occurring mutations.
Whereas 286 mutations were found by assays interrogating known
or candidate oncogenes, 131 mutations were observed in TS
genes. Thus, the OncoMap platform provided more extensive
mutation information than earlier mutation profiling efforts which
focused exclusively on oncogene mutations. As expected, the
distribution of mutations reflected patterns previously observed in
human tumors, although the frequency of TS mutations was lower
(reflective of the reduced coverage of such mutations by
OncoMap). Examples include PIK3CA (26%) and TP53 (13%)
mutations in breast cancer; APC (11%), BRAF (10%), KRAS (38%),
PIK3CA (11%) and TP53 (9%) mutations in colorectal cancer, and
EGFR (12%), KRAS (23%) and STK11 (8%) mutations in lung
cancer. The expected mutation distributions were observed in
both fresh frozen and FFPE specimens, underscoring the potential
utility of OncoMap in the clinical setting.
Figure 1. The OncoMap process and performance in fresh frozen and FFPE-derived DNA. A. An overview of the OncoMap process from
tumor to mutation profile. See text for details. B. Receiver operator characteristic curves (ROCs) show the sensitivity and specificity for various cutoff
values on the sample score of the validation samples. ROCs are plotted for fresh frozen (left) and FFPE-derived (right) DNAs, using bidirectional KRAS
assays and Illumina data as a truth-set (see Methods S1).
doi:10.1371/journal.pone.0007887.g001
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Mutations Predicting Response to Targeted Therapies
Table 2 indicates a set of ‘‘actionable’’ cancer gene mutations
identified herein. The OncoMap platform robustly detected
mutations that constitute established markers of response to
targeted therapies. For example, EGFR mutations predictive of
response to erlotinib and gefitinib were identified at the expected
frequency (12%) in non-small cell lung cancer, and KIT mutations
linked to sensitivity to imatinib and nilotinib were detected in 76%
of GISTs. Interestingly, ERBB2 mutations were detected in four
gastric adenocarcinomas, raising the possibility of testing a HER-2
inhibitor such as trastuzumab in gastric cancer patients selected
based on this genetic criterion [8].
Several tumors harbored mutations that may predict response
to investigational agents. For example, BRAFV600E mutations were
identified in colorectal (n = 16), ovarian (n= 1), thyroid (n = 4) and
endometrial (n = 1) cancers, as well as pediatric gangliogliomas
(n = 22; see below). Tumors harboring these mutations may
respond to a selective BRAF inhibitor[6,9]. We also identified 96
samples across seven different cancer types (breast n= 14,
colorectal n = 24, endometrial n = 15, esophageal n = 4, gastric
n = 34, prostate n= 3, and pediatric astrocytoma n=2) harboring
mutations in either PIK3CA or PTEN. These mutations might be
expected to enrich for tumors responsive to the PI3 kinase
inhibitors currently in development.
Mutations Predicting Resistance to Targeted Therapies
Along with mutations that confer heightened sensitivity to
targeted therapies, OncoMap robustly detected mutations associated
with resistance to several agents. Established examples include KRAS
mutations in non-small cell lung cancer (23%) and colorectal cancer
(38%) that confer resistance to erlotinib, gefitinib (lung) or cetuximab
(colorectal)[4,10,11]. While 94% of KRAS mutations identified
localized to codons 12 or 13, 6% occurred elsewhere in the gene
(most commonly at codon 61). Since most studies of KRAS-associated
resistance have focused exclusively on codons 12 and 13[3,12,13],
OncoMap identified additional KRAS mutations that may influence
sensitivity to anti-EGFR treatment. OncoMap also identified an
HRASmutation in a lung adenocarcinoma and an NRASmutation in
a colorectal adenocarcinoma. Mutations involving alternate RAS
isoforms are rare in these cancer types; conceivably, these might also
confer resistance to anti-EGFR therapy.
Mutation profiling also identified mutations that confer
‘‘secondary’’ resistance to targeted therapies (e.g., resistance alleles
arising during the course of targeted therapy). In GIST tumors,
where 31 KIT mutations were identified in 25 samples; both
primary (imatinib-responsive) and secondary (imatinib-resistant)
KIT mutations were observed, in keeping with prior mutation
profiling studies [7]. In particular, several KIT mutations involving
exon 9 (KIT Y503_or F504insAY; 5 cases) were detected in
untreated GIST tumors. These mutations are associated with an
increased drug requirement to elicit a clinical response [14,15]. A
PDGFRA mutation (D842V) predictive of resistance to imatinib
[15] was also identified in one GIST sample.
The AKT1E17K mutation has previously been reported in breast,
colorectal and ovarian cancer. The OncoMap platform identified
rare AKT1 mutations in these tumor types, as well as single
AKT1E17K instances in endometrial, esophageal squamous, gastric,
and prostate cancers. This mutation may predict resistance to PI3
kinase inhibition (and conceivably receptor tyrosine kinase
inhibition) in some contexts [16].
Cancers with Co-Occurring ‘‘Actionable’’ Mutations
The presence of co-occurring mutations involving critical
cancer genes may modify the clinical response to single-agent
targeted therapy. Here, 20 adenocarcinomas (10 colorectal, two
endometrial and 8 gastric) exhibited co-occurring PIK3CA and
KRAS mutations. While coincident mutations in these genes have
previously been reported in cancers of the large intestine [17],
PIK3CA and KRAS mutations have typically exhibited a mutually
exclusive pattern of occurrence in endometrial cancer [18,19]. An
endometrial adenocarcinoma with co-occurring FGFR2 and PTEN
mutations was also identified. Two tumors harbored coincident
BRAF and PTEN mutations (one endometrial, one colorectal), and
an additional colorectal sample contained both a PIK3CA and a
BRAF mutation. These tumors might be expected to exhibit
resistance to receptor tyrosine kinase inhibition.
Molecular Classification of Pediatric Brain Tumors by
Cancer Gene Mutation Profiling
The ability to perform robust mutation profiling of clinical and
archival tumor tissue may promote systematic molecular charac-
terization of ‘‘orphan’’ cancers, including some pediatric tumors
where sufficient tissue is often lacking. To explore this hypothesis,
OncoMap was used to query a series of pediatric low-grade
gliomas (LGGs) whose mutation spectrum is incompletely defined.
This analysis included genomic DNA from 127 pediatric and 28
adult gliomas (for comparison) spanning five histologic subtypes of
pilocytic astrocytoma, ganglioglioma, and diffuse astrocytoma.
Candidate Prognostic or Therapeutic Targets in Pediatric
Brain Tumors
Several potentially ‘‘actionable’’ cancer genes were found
mutated in pediatric LGAs. Examples include PDGFRA (n = 1)
and PIK3CA (n = 2), which may predict response to existing drugs
(e.g., imatinib or nilotinib) or agents in development (e.g., PI3
kinase inhibitors). Two pediatric LGAs harbored mutations in
MYC, a well established oncogene homologue of NMYC, which is
amplified and indicative of poor prognosis in pediatric neuroblas-
toma [20,21]. Thus, tumor mutation profiling may refine patient
stratification and/or disease prognosis in some pediatric brain
cancers.
BRAFV600E Mutations Are Common in Pediatric
Gangliogliomas
Duplication of the BRAF locus has been reported as the most
frequent aberration in pediatric LGAs (66% [18]), whereas
activating point mutations in BRAF occur less commonly (4–6%)
[22], [23]. We identified activating BRAFV600E mutations in 11%
(10/88) of pediatric LGAs—a higher percentage than previously
reported [22,23]. Interestingly, the BRAFV600E mutation was most
prevalent within the ganglioglioma subtype of pediatric LGAs
(classical and non-classical; 8/14 tumors, p = 0.00005), as shown in
Fig. 2. BRAFV600E mutations were not identified in any of the
adult tumors examined, although TP53 mutations commonly
occurred in this setting (10/28 cases). Conversely, only 2 pediatric
gliomas harbored a TP53 mutation; in both cases, this was
coincident with another mutation (EGFR and FLNB, respectively).
These results suggest that OncoMap might facilitate classification
of low-grade astrocytomas and other rare tumor types based on
genetic criteria.
Discussion
Clinical oncology is in the midst of transition from a treatment
paradigm dictated primarily by the anatomic site of tumor origin
to one in which genetic and/or molecular characteristics play
a decisive role in guiding choice of therapy. Moreover, the
Cancer Gene Mutation Profiling
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proliferation of targeted agents in development and clinical
practice necessitates concomitant implementation of companion
diagnostic approaches that enrich for subpopulations most likely to
respond to a drug. New diagnostic approaches are therefore
needed to profile any tumor for pivotal genetic mutations in
multiple cancer genes simultaneously, in contrast to most existing
tests that focus on single genes (or proteins).
In this study, we adapted genotyping-based mutation profiling
for the characterization of both frozen and FFPE-derived tumor
specimens spanning 12 cancer types. We robustly detected cancer
gene mutations that direct clinical use and predict resistance to
existing agents such as tyrosine kinase inhibitors (e.g., EGFR and
KRAS mutations). We also identified multiple mutations that may
Table 2. Druggable or actionable mutations identified in this
study.
Tissue Type Gene Amino acid N %
Brain (astrocytoma,
ganglioglioma, glioblastoma)
BRAF V600E 22 14.2
EGFR T263P 1 0.6
PDGFRA D842V 1 0.6
PIK3CA R88Q 1 0.6
H1047R 1 0.6
Breast (lobular and ductal
carcinoma)
AKT1 E17K 1 1.9
PIK3CA R88Q 1 1.9
N345K 1 1.9
E542K 1 1.9
E545K 2 3.8
H1047R 9 17.0
Colon (adenocarcinoma) AKT1 E17K 1 0.6
BRAF D594G 2 1.3
L597Q 1 0.6
V600E 13 8.2
KRAS A146T 1 0.6
G12A/C/D/S/V 45 28.3
G13C/D 13 8.2
Q61H/L 2 1.3
NRAS Q61K 1 0.6
PIK3CA R88Q 1 0.6
E542K 2 1.3
E545G/K 13 8.2
H1047R 2 1.3
PTEN R130Q/* 2 1.3
R233* 2 1.3
K267fs*9 2 1.3
Endometrium (adenocarcinoma) AKT1 E17K 1 4.3
BRAF G466A 1 4.3
FGFR2 S252W 1 4.3
C382R 1 4.3
KRAS G12A/V 3 13.0
G13D 1 4.3
PIK3CA R88Q 1 4.3
C420R 1 4.3
H701P 1 4.3
H1047R 4 17.4
PTEN R130G/Q/* 6 26.1
R173H 1 4.3
N323fs*2 1 4.3
Esophagus (adenocarcinoma
and squamous carcinoma)
AKT1 E17K 1 0.9
PIK3CA E542K 2 1.7
E545K 1 0.9
H1047R 1 0.9
Gastric (adenocarcinoma) AKT1 E17K 1 0.5
EGFR L858M 1 0.5
ERBB2 L755S 3 1.5
Tissue Type Gene Amino acid N %
V777L 1 0.5
KRAS G12C/D 11 5.5
G13C/D 5 2.5
PIK3CA R88Q 1 0.5
C420R 2 1.0
E542K 8 4.0
E545K 8 4.0
H1047R 10 5.0
PTEN K267fs*9 3 1.5
N323fs*2 1 0.5
N323fs*21 1 0.5
GI tract (GIST) KIT Y503_F504insAY 7 21.2
W557G 2 6.1
W557_K558del 2 6.1
W557_V559.C/F 4 12.1
V559D 1 3.0
V560D 2 6.1
V560del 2 6.1
L576P 1 3.0
K642E 2 6.1
V654A 3 9.1
D816H 1 3.0
N822K 2 6.1
Y823D 1 3.0
PDGFRA D842V 1 3.0
Kidney (renal cell carcinoma) VHL L89H 1 3.8
Lung (adenocarcinoma) EGFR L858R 3 11.5
HRAS Q61L 1 3.8
KRAS G12C/D 4 15.4
Q61H 2 7.7
Ovary (adenocarcinoma) BRAF V600E 1 11.1
Prostate (adenocarcinoma) AKT1 E17K 1 1.1
FGFR3 F384L 1 1.1
PIK3CA H1047R 1 1.1
G1049R 1 1.1
PTEN R173H 1 1.1
Thyroid (papillary carcinoma) BRAF V600E 4 57.1
doi:10.1371/journal.pone.0007887.t002
Table 2. Cont.
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guide the use of emerging agents. Finally, in a specific investigation of
pediatric low-grade astrocytomas, we demonstrated the special value
this platform may have for rare ‘‘orphan’’ cancers by identifying
mutations that may inform molecular classification as well as new
therapeutic avenues for children with these malignancies.
Diagnostic interventions that successfully introduce tumor
mutation profiling to clinical practice must circumvent several
technical and logistical hurdles. Chief among these is the
attainment of robust performance in samples derived from FFPE
and/or archival tumor material. We found that the OncoMap
platform achieved nearly 100% specificity in both fresh/frozen
and FFPE-derived tumor DNA, indicating that false positive
mutation calls are likely to be relatively rare with this approach. It
should be noted, however, that achieving this level of specificity
required the implementation of an analytical sequence in which
raw genotyping data is subjected to automated base calling
followed by manual review of candidate mutations and validation
of all candidates using alternative genotyping chemistries. Thus,
clinical implementation of OncoMap must incorporate both
genomic data generation and bioinformatic analytical expertise
into a molecular pathology or clinical diagnostic setting.
The sensitivity of OncoMap is influenced by inherent techno-
logical parameters, individual mutation assay performance charac-
teristics, and the quality and purity of tumor tissue. The 89–94%
assay sensitivity observed in this study is sufficient for many
translational and clinical applications; however, there are of course
circumstances where even higher assay sensitivities will be desirable.
Enrichment of tumor cells using core needle dissection or laser-
capture microdissection prior to mutation profiling may offer one
avenue to enhance sensitivity, particularly in tumors where the
stromal or inflammatory content is high. At the same time, the
sensitivity of OncoMap vastly exceeds that of Sanger sequencing,
which remains the gold standard for many genetic diagnostic
approaches. Furthermore, the breadth of cancer genes and specific
mutations interrogated by OncoMap—supported by the aforemen-
tioned rigorous sensitivity and specificity determinations—substan-
tially exceeds that of existing commercial mass spectrometric-based
genomic profiling approaches[24].
Genomically guided therapies may play an especially prominent
role in rare tumors where large randomized trials are often
impractical. To test the ability of the OncoMap to identify
uncommon and/or sample-limited tumors that may benefit from
specific classes of therapeutic agents, we profiled a panel of pediatric
low-grade gliomas for common cancer gene mutations. Knowledge
of the genetic abnormalities present in pediatric LGAs is limited,
though recent studies have identified BRAF translocations, chro-
mosomal duplications, and occasional base mutations in low-grade
astrocytomas[18,25], as well as diverse mechanisms for activating
the ERK/MAPK pathway in pilocytic astrocytomas [23]. These
findings suggest that the small molecule inhibitors of BRAF already
in adult trials may also represent promising therapeutics for subsets
of these tumors. Our results indicate that the frequency of BRAF
point mutations in pediatric LGAs as a whole may be higher than
previously reported, and specifically that gangliogliomas possess
BRAFV600E mutations at very high frequency. This observation may
also aid in diagnostic identification of these tumors. Gangliogliomas,
which tend to be indolent tumors, may therefore share some
properties with cutaneous nevi, whose melanocyte precursors also
derive from the nervous system (neural crest), exhibit indolent
growth, and where the BRAFV600E mutation is also highly prevalent.
We also identified several mutations not previously reported in
pediatric astrocytoma, some of which (EGFR, PIK3CA, PDGFRA)
represent potentially actionable targets. In concordance with
previous reports [22,26,27] we observe that mutations in genes
frequently observed in adult anaplastic astrocytomas and/or
glioblastomas, such as TP53 or PTEN, are only rarely encountered
in pediatric pilocytic and low-grade diffuse astrocytomas.
Although our findings support the clinical feasibility of high-
throughput tumor mutation profiling, we recognize that the mass
spectrometric genotyping approach has certain limitations that
may preclude its implementation as a definitive cancer diagnostics
platform. These include the finite number of specific point
mutations that can be assayed (designated a priori within a subset
of cancer genes), difficulties in designing genotyping assays that
identify small insertions or deletions (‘‘in-dels’’) larger than ,50bp
in size, an inability to detect most TS gene mutations (which may
occur anywhere within the gene, not just ‘‘hotspot’’ regions) or
additional genomic alterations such as high-level gene amplifica-
tions or deletions that may also affect key cancer genes, and the
somewhat labor-intensive nature of manual review and orthogonal
assay validation. Over the long term, the adaptation of new
genomics technologies such as second generation sequencing may
offer a unifying approach to comprehensive tumor mutation
profiling. However, the OncoMap platform may offer one
immediate avenue by which systematic mutation profiling might
be initiated to guide clinical trial design as well as use of existing
targeted agents across many cancer types.
In summary, this study represents the first large-scale applica-
tion of the OncoMap platform for tumor mutation profiling in the
clinical and archival setting. These results therefore enliven a
framework wherein systematic tumor profiling might emerge as a
widely feasible means to guide patient stratification for rational
cancer therapeutics. Despite the inherent complexity of cancer,
incorporating the growing knowledge of the molecular basis of
cancer into both large-scale molecular epidemiologic studies and,
ultimately, clinical decision making should ultimately speed the
advent of more effective anticancer therapies.
Supporting Information
Methods S1 Profiling critical cancer gene mutations in clinical
tumor samples.
Figure 2. BRAFV600E mutations detected in archival samples of
pediatric gliomas. Abbreviations: PA - pilocytic astrocytoma,WHO grade I;
LGG, nos – low-grade glioma, not otherwise specified, WHO grade I or II;
GG – ganglioglioma; A2 – astrocytoma, WHO grade II; HG – high-grade
glioma, WHO grade III or IV. Parentheses indicate total number of
samples (in chart) or number of samples with indicatedmutation (outside
chart).
doi:10.1371/journal.pone.0007887.g002
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Found at: doi:10.1371/journal.pone.0007887.s001 (0.07 MB
DOC)
Table S1 OncoMap 3 core PCR primer and extension probe
sequences.
Found at: doi:10.1371/journal.pone.0007887.s002 (0.13 MB
XLS)
Table S2 KRAS G12 PCR primer sequences used to generate
amplicons for Sanger and Illumina sequencing.
Found at: doi:10.1371/journal.pone.0007887.s003 (0.03 MB
XLS)
Figure S1 Performance of OncoMap in fresh frozen and FFPE-
derived DNA. Receiver operator characteristic curves (ROCs) are
plotted for fresh frozen (left panel) and FFPE-derived (right panel)
DNAs, against unidirectional OncoMap KRAS assays, using
Illumina data as a truth-set (see Methods S1).
Found at: doi:10.1371/journal.pone.0007887.s004 (0.06 MB PPT)
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